Kwality Pharmaceuticals Ltd (KPL) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Kwality Pharmaceuticals Ltd reported sales of ₹162 Cr, operating profit of ₹41 Cr (OPM 25%) and net profit of ₹26 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
KPL quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 90 84 116 111 111 123 157 162 Expenses 70 67 90 87 86 93 118 121 Operating Profit 20 18 26 24 25 30 39 41 OPM 22% 21% 22% 22% 23% 24% 25% 25% Other Income 0 1 1 0 1 0 1 1 Interest 3 2 2 3 3 2 3 3 Depreciation 5 5 5 5 5 5 5 5 Profit before tax 13 11 19 17 18 22 32 34 Tax 33% 25% 24% 30% 23% 28% 20% 25% Net Profit 8 9 14 12 14 16 25 26 EPS in Rs 8.16 8.22 13.96 11.5 13.61 15.43 24.38 24.69
KPL profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 456 251 307 370 503 554 Expenses 285 190 241 290 385 419 Operating Profit 172 61 66 80 118 135 OPM 38% 24% 22% 22% 24% 24% Other Income 4 -14 -5 2 2 2 Interest 3 7 10 10 11 11 Depreciation 11 15 20 18 20 20 Profit before tax 162 26 31 54 89 106 Tax 26% 25% 24% 26% 25% - Net Profit 120 19 24 40 67 81 EPS in Rs 115.64 18.67 22.94 38.41 64.91 78.11 Dividend Payout 0% 0% 0% 0% 0% -
KPL balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 10 10 10 - 10 Reserves 190 214 254 - 321 Borrowings 90 98 112 - 130 Other Liabilities 70 72 71 - 130 Total Liabilities 361 394 447 - 592 Fixed Assets 120 139 146 - 156 CWIP 14 0 0 - 17 Investments 0 0 0 - 0 Other Assets 226 255 302 - 420 Total Assets 361 394 447 - 592
KPL cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 61 41 43 53 17 Cash from Investing Activity -63 -48 -26 -29 -35 Cash from Financing Activity 6 1 -17 -14 7 Net Cash Flow 3 -6 -1 10 -11 Free Cash Flow 5 -4 17 28 -29 CFO/OP 59% 78% 67% 85% 32%
KPL ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 55 104 136 152 203 Inventory Days 97 310 187 167 111 Days Payable 63 117 106 112 144 Cash Conversion Cycle 90 297 217 208 170 Working Capital Days 60 118 101 98 128 ROCE 98% 19% 16% 18% 24%